本公司及董事会全体成员保证信息披露的内容真实、准确和完整，没有虚假记载、 误导性陈述或重大遗漏。 南京红太阳股份有限公司（以下简称"公司"、"红太阳股份"或"上市公司"） 于近日收到深圳证券交易所下发的《关于对南京红太阳股份有限公司 2024 年年 报的问询函》（公司部年报问询函〔2025〕第 159 号）（以下简称"问询函"）， 要求公司就有关问题做出书面说明，并将有关说明材料报送深圳证券交易所，同 时抄送江苏证监局上市公司监管处。收到问询函后，公司和董事会高度重视，并 及时组织相关部门和人员、中介机构就问询函所涉及事项进行逐项核实与回复， 年审会计师和律师就有关事项进行核查并发表核查意见。现将相关问题的回复公 告如下： 1.2024 年 12 月 6 日，南京中院认定你公司重整计划执行完毕，裁定终结了 你公司重整程序，重整投资人（含其指定主体）通过认购转增股票、代偿资金 占用、业绩补偿等方式清偿债权。年报显示，你公司 2024 年度确认与重整事项 相关的损益（以下简称重整损益）共计 138,538.07 万元，其中，你公司根据审 查确认债权补充确认相关支出共计 159,858.72 万元，根据终止债务确认 ...

证券代码：000525 证券简称：ST 红太阳 公告编号：2025－029 南京红太阳股份有限公司 关于公司股票交易撤销其他风险警示暨停复牌的公告 本公司及董事会全体成员保证信息披露的内容真实、准确和完整，没有虚假记载、 误导性陈述或重大遗漏。 重要提示： 1、南京红太阳股份有限公司（以下简称"公司"）股票交易于 2025 年 6 月 12 日停牌一天，于 2025 年 6 月 13 日开市起复牌。 2、公司股票自 2025 年 6 月 13 日开市起撤销其他风险警示，股票简称由"ST 红太阳"变更为"红太阳"，股票代码仍为"000525"，撤销其他风险警示后，公司 股票交易日的涨跌幅限制由 5%变更为 10%。 3、公司因 2020 年至 2023 年度均被出具否定意见的内部控制审计报告，公 司存在最近一年（2023 年度）被出具否定意见的内部控制审计报告而触及的其 他风险警示情形，公司股票被实施其他风险警示。2024 年度公司内部控制审计 报告的意见类型为"标准无保留意见"，且公司 2023 年度内部控制审计报告否定 意见涉及事项影响已消除。 一、股票种类、简称、股票代码以及股票停复牌起始日 1、股票种类 ...

Core Viewpoint - ST Hongtai (000525) will suspend trading for one day on June 12, 2025, and resume trading on June 13, 2025, with the stock name changing from "ST Hongtai" to "Hongtai" and the stock code remaining the same [1] Summary by Relevant Sections - Trading Suspension and Resumption - The company will suspend its stock trading on June 12, 2025, and will resume trading on June 13, 2025 [1] - Change in Stock Name and Code - The stock name will change from "ST Hongtai" to "Hongtai," while the stock code "000525" will remain unchanged [1] - Adjustment of Trading Limits - The daily price fluctuation limit for the stock will increase from 5% to 10% starting June 13, 2025 [1] - Audit Report Status - The company received a negative opinion on its internal control audit reports for the years 2020 to 2023, which triggered other risk warning situations [1] - The internal control audit report for the year 2024 is expected to be standard with an unqualified opinion, and the issues related to the negative opinion in the 2023 report have been resolved [1]

Core Viewpoint - ST Hongtai announced a price adjustment for its 97% chlorantraniliprole product to 300,000 yuan per ton, a more than 40% increase compared to last year's low of 210,000 yuan per ton, primarily due to limited upstream raw material supply and rising costs [1][3]. Industry Overview - Chlorantraniliprole is the world's largest insecticide, with annual global sales exceeding $2 billion. After the expiration of its compound patent in China in August 2022, market prices continued to decline, with a cumulative drop of 34.38% in 2024. However, since 2025, prices have rebounded due to low effective capacity release influenced by intermediates and operating rates, rising to 228,000 yuan per ton on May 25, an increase of 8.57% [3]. - Currently, there are over 100,000 tons per year of chlorantraniliprole production capacity under construction or planning in China, but the progress of planned capacity construction has slowed due to the impact of intermediate K amine supply and declining raw material prices [3]. Market Reaction - Following the price adjustment announcement, the pesticide sector continued to show strength on June 9, with stocks such as Changqing Co. and Guangkang Biochemical hitting historical highs, and ST Hongtai and other stocks also rising [3]. - Analysts generally believe that chlorantraniliprole prices are likely to experience a phase of upward momentum. Future project approvals and production regulations involving hazardous chemical reactions such as nitration and chlorination are expected to become stricter, benefiting leading companies in the chemical industry that can maintain stable production of existing products [3]. Company Responses - Due to changes in market supply dynamics, investor interest in companies involved in chlorantraniliprole has increased, prompting several listed companies to respond. Lianhua Technology stated that it provides advanced intermediates through a CDMO model and does not directly produce the product, indicating limited overall impact on the company. Huailong Co. is steadily advancing its chlorantraniliprole raw material and intermediate project with an annual output of 2,000 tons. Lier Chemical is orderly constructing a 5,000 tons/year production facility. Changqing Co. confirmed that its insecticides are currently in normal production. Liming Co. noted that if chlorantraniliprole supply tightens, it would boost demand for alternatives such as abamectin and methomyl [4].

Core Viewpoint - The price of 97% chlorantraniliprole has been adjusted to 300,000 yuan/ton due to limited supply of upstream raw materials, marking an increase of over 40% compared to the low point of 210,000 yuan/ton last year. This price adjustment is expected to lead to a phase of price increase in the market for chlorantraniliprole [1][2]. Industry Summary - Chlorantraniliprole has a global annual sales exceeding $2 billion, making it the largest insecticide worldwide. It was discovered by the former DuPont company in 2000 and was first launched in 2008. The expiration of its compound patent in China on August 13, 2022, significantly changed the market landscape [2]. - Following the patent expiration, the market price of chlorantraniliprole continued to decline, with a cumulative drop of 34.38% from 320,000 yuan/ton at the beginning of 2024 to 210,000 yuan/ton by the end of the year. However, since 2025, prices have rebounded from 210,000 yuan/ton to 228,000 yuan/ton as of May 25, 2025, reflecting an increase of 8.57% [2]. - Currently, over 100,000 tons/year of chlorantraniliprole production capacity is under construction or planned in China. However, actual progress has been hindered by the supply of intermediates and the continuous decline in raw material prices [2]. Company Responses - Lianhua Technology announced that it provides advanced intermediates for chlorantraniliprole through a CDMO business model and does not directly produce chlorantraniliprole. The company has a long-term partnership with its client and has not received any notifications regarding increased demand for related products [3]. - Huayong Co. stated that it has an annual production capacity of 2,000 tons of chlorantraniliprole and intermediates, with steady progress in project construction [3]. - Lier Chemical expressed optimism about the market prospects for chlorantraniliprole and is currently constructing a production facility with a capacity of 5,000 tons/year [3]. - Liming Co. indicated that its products cover various categories of insecticides, and if chlorantraniliprole supply tightens, it may boost the demand for its widely used insecticides, such as abamectin and methomyl, which have overlapping efficacy with chlorantraniliprole [4]. - Industry insiders noted that if the price of chlorantraniliprole rises sharply in the short term, downstream users may opt for alternative insecticides, increasing the demand for substitutes [4].

南京红太阳股份有限公司 本公司及董事会全体成员保证信息披露的内容真实、准确和完整，没有虚假记载、 误导性陈述或重大遗漏。 一、股票交易异常波动的具体情况 南京红太阳股份有限公司（以下简称"公司"） （证券代码：000525， 证券简称：ST红太阳）股票连续三个交易日（2025年6月5日、6月6 日、6月9日）收盘价涨幅累计偏离13.76%，根据深圳证券交易所的相 关规定，属于股票交易异常波动情形。 二、公司关注、核实情况说明 证券代码：000525 证券简称：ST 红太阳 公告编号：2025－027 生买卖公司股票的行为。 三、是否存在应披露而未披露信息的说明 公司董事会确认，除公司已披露的信息外，公司目前没有任何根 据《股票上市规则》等有关规定应予以披露而未披露的事项或与该事 项有关的筹划、商谈、意向、协议等；董事会也未获悉公司有根据《股 票上市规则》等有关规定应予以披露而未披露的、对公司股票交易价 格产生较大影响的其他信息。 四、风险提示 公司将严格按照《股票上市规则》等有关法律法规及其规章制度 要求，及时披露相关事项的进展。公司指定的信息披露媒体为《中国 证券报》《证券时报》及巨潮资讯网，公司所有信息均 ...

证券代码：000525 证券简称：ST 红太阳 公告编号：2025－027 南京红太阳股份有限公司 3、截至目前，除已披露的信息外，公司、公司控股股东及实际 控制人不存在关于公司的应披露而未披露的重大事项。 关于股票交易异常波动暨风险提示的公告 本公司及董事会全体成员保证信息披露的内容真实、准确和完整，没有虚假记载、 误导性陈述或重大遗漏。 一、股票交易异常波动的具体情况 南京红太阳股份有限公司（以下简称"公司"）（证券代码：000525， 证券简称：ST红太阳）股票连续三个交易日（2025年6月5日、6月6 日、6月9日）收盘价涨幅累计偏离13.76%，根据深圳证券交易所的相 关规定，属于股票交易异常波动情形。 二、公司关注、核实情况说明 针对公司股票交易异常波动，公司董事会向公司、公司控股股东 云南合奥产业合伙企业（有限合伙）及实际控制人曲靖高新技术产业 开发区管理委员会就相关事项进行了核实，现就有关情况说明如下： 1、目前，公司生产经营情况正常，公司高度重视安全生产并持 续开展环保治理工作，公司内外部经营环境未发生重大变化。2024 年度，公司实现营业收入 3,007,032,836.24 元，同比下降 ...

ST红太阳：公司生产经营正常 无应披露而未披露的重大事项 智通财经6月9日电，ST红太阳(000525.SZ)公告称，公司股票连续三个交易日收盘价涨幅累计偏离 13.76%，属于股票交易异常波动情形。经核实，公司生产经营情况正常，内外部经营环境未发生重大 变化。公司未发现近期公共传媒报道可能或已经对公司股票交易价格产生较大影响的未公开重大信息。 公司控股股东及实际控制人在股票异常波动期间未发生买卖公司股票的行为。 ...

Group 1 - The agricultural pesticide sector continues its strong performance, with Changqing Co., Ltd. achieving a two-day consecutive limit-up [1] - Guangkang Biochemical surged over 15%, reaching a new historical high, while Lianhua Technology approached the limit-up [1] - Other companies such as Nuobixin, Yabenn Chemical, Hailier, and Huillong also experienced gains [1] Group 2 - On June 5, ST Hongtaiyang announced a price adjustment for its 97% chlorantraniliprole product, raising the price to 300,000 yuan per ton, with limited supply [1] - This price increase represents a more than 40% rise compared to the market's low point of 210,000 yuan per ton last year [1]

特别申明： 本订阅号中所涉及的证券研究信息由光大证券研究所编写，仅面向光大证券专业投资者客户，用作新媒体形势下研究 信息和研究观点的沟通交流。非光大证券专业投资者客户，请勿订阅、接收或使用本订阅号中的任何信息。本订阅号 难以设置访问权限，若给您造成不便，敬请谅解。光大证券研究所不会因关注、收到或阅读本订阅号推送内容而视相 关人员为光大证券的客户。 报告摘要 受政策及监管的影响，我国的农药产品结构不断优化 点击注册小程序 查看完整报告 ST红太阳上调氯虫苯甲酰胺价格，氯虫苯甲酰胺成本端支撑偏强 友道化学的工厂爆炸将影响氯虫苯甲酰胺原药的短期供应，从而有望推升价格。此外，目前氯虫苯甲酰胺的上 游中间体K胺市场供应紧缺，氯虫苯甲酰胺的成本端支撑偏强。根据百川盈孚数据，5月30日，氯虫苯甲酰胺 市场部分成交价格参考23万元/吨，相较5月29日的涨幅为2.22%。25年6月5日，ST红太阳发布调价函，称由于 上游原材料供应受限，主要原材料货紧价扬，导致公司氯虫苯甲酰胺成本急剧上升，受此影响，97%氯虫苯甲 酰胺产品价格调整至30万元/吨，限量供应。行业产能布局方面，ST红太阳具有年产2000吨氯虫苯甲酰胺的产 能，另有 ...